5Osamu Ogawa,Masanori Iinuma,Kazunari Sato,Ryusei Sasaki,Naotake Shimoda,Shigeru Satoh,Tetsuro Kato. Circulating prostate-specific antigen mRNA during radical prostatectomy in patients with localized prostate cancer: with special reference to neoadjuvant hormonal therapy[J] 1999,Urological Research(4):291～296
3[1]Mulder P, Figlin R, de Kemion LB, et al. Renal cell carcinoma:recent progress and future direction [J].Cancer Res, 1997, 57:5189-5195.
4[2]Yagoda A, Abi-Bached B, Petrylak D. Chemtherapy for advanced renal cell carcinoma:1983-1993[J]. Semin Oncol, 1995,22:42.
5[4]Yang JC, Topalian SL, Parkinson D, et al. Randomized comparision of high-dose and low-dose intravenous IL-2for the therapy of meta static renal cell carcinoma:an interim report[J]. J Clin Oncol, 1994,12:1572-1576.
6[5]Lopez hanninen E, Kirehner H, Atzpodien J. IL-2 bazed home therapy of merasratic RCC:risks and benefits in 215consecutive single institution patients [J].J Urol, 1996,158:19-25.
7Basse,Per H.Cancer lmmunotherapy with Interleukin-2-Activated Natural Killer Cells[J].Mol Biotechnol,2002,21(2):161.
8Yamada,Hiroshi,Matsumoto,et al.Murine IL-2 Secreting Recombinant Bacillus Calmette-Guerin Augments Macrophage-Mediated Cytotoxicity Against Muring Bladder Cancer MBT-2[J].Urol,2003,164(2):526.
9Yang,James C,Sherry,et al.Randomized Study of High-DoSe and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer[J].J Clin Oncol,2003,21(16):3127.
10O'donnell,Michael A,Luo,et al.Interleukin-12 Immunotherapy of Murine Transitional Cell Carcinoma of the Bladder:Dose Dependent Tumor Eradication and Generation of Protective Immunity[J].J Urol,2004,171(3):1330.
